Qiagen launches QIAstat-Dx Rise
November 2025—Qiagen launched QIAstat Dx Rise, an FDA-cleared automated syndromic testing system for hospitals and laboratories.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Bio-Rad launches specialty immunoassay controls in Europe
November 2025—Bio-Rad Laboratories launched Specialty Immunoassay Plus in Europe, a comprehensive immunoassay quality control product for specialty immunoassay testing procedures.
Molecular Designs submits respiratory panel for 510(k) clearance
November 2025—Molecular Designs submitted a 510(k) premarket notification to the FDA for its SimplicityDx Respiratory panel, designed to detect SARS-CoV-2, influenza A, influenza B, and RSV.
Quest launches advanced PGx test service
November 2025—Quest Diagnostics launched a pharmacogenomic laboratory test service to help providers understand a patient’s genetic response to drug therapies.
Guardant, PathGroup partner to expand access to Shield test
November 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test for colorectal cancer screening.
Data presented at ACEP25 show the utility of MeMed BV
November 2025—Presentations at the American College of Emergency Physicians Scientific Assembly 2025 highlighted MeMed BV’s effectiveness in distinguishing between bacterial and viral infections.
Tosoh gets clearance for next-gen GR01 HbA1c analyzer
November 2025—Tosoh Bioscience received FDA clearance for its HLC 723-GR01 analyzer, which uses proprietary technology to deliver A1c results in 50 seconds and detect common hemoglobin variants.
Abbott gets expanded approval for HPV assay
November 2025—FDA approves Abbott’s Alinity m HR HPV assay for self-collected vaginal samples in clinical settings.
Quickvue Influenza + SARS test available for professional use
November 2025—QuidelOrtho’s Quickvue Influenza + SARS test, a CLIA-waived immunoassay, is now available for professional use.
CytoCell KMT2A FISH probe kit granted de novo classification
November 2025—FDA granted de novo classification for OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax’s menin inhibitor, Revuforj.